Results 11 to 20 of about 14,098 (242)

Early Enrollment in Diabetes Pay-for-Performance Program Reduced Loss of Life Expectancy in Newly-Diagnosed Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal
Background Diabetes is associated with reduced lifespan. To explore pay-for-performance (P4P) program and life expectancy (LE), we investigated the impact of interval between diabetes diagnosis and enrollment in P4P program on loss-of-LE among patients ...
Yu-Ching Chen, Wei-Ming Wang, Boniface J. Lin, Jung-Der Wang, Li-Jung Elizabeth Ku   +4 more
doaj   +1 more source

How can Saudi Arabia reform its public hospital payment models? A narrative review

Saudi Pharmaceutical Journal, 2020
Background: The cost of Saudi healthcare continues to rise at an alarming rate, putting the sustainability of the public healthcare system into question.
Yazed AlRuthia, Norah Abdulaziz Bin Aydan, Nora Sulaiman Alorf, Yousif Asiri   +3 more
doaj   +1 more source

Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model

Frontiers in Medical Technology, 2023
BackgroundAntimicrobial resistance (AMR) is a growing threat to global health. With pathogenic bacteria inevitably becoming more resistant to existing antimicrobials, mortality and costs due to AMR will significantly increase over the next few decades if
Marieke Schurer, Renu Patel, Marjolijn van Keep, Jake Horgan, Suzette Matthijsse, Matthew Madin-Warburton   +5 more
doaj   +1 more source

Incentive Compatible Reimbursement Schemes for Physicians [PDF]

SSRN Electronic Journal, 2010
Physicians choose capacity before demand materializes; actual demand may be higher or lower than capacity. If a physicians capacity exceeds demand, she may have an incentive to overtreat, i.e., she may provide unnecessary treatments to use up idle capacity.
openaire   +5 more sources

Understanding the Public Policy of Global Budget Payment Reform Improves the Quality of Public Healthcare From the Perspective of Patients in China

Frontiers in Psychology, 2022
The transformation from the retrospective to the prospective payment system is significant to improve the quality of public healthcare (QPH). This article used the quasi-natural experiment of the global budget payment reform of government (GBPRG) in ...
Lele Li, Shuo Zhang
doaj   +1 more source

An empirical study of the impact of generic drug competition on drug market prices in China

Frontiers in Public Health, 2023
IntroductionGeneric substitution is encouraged to reduce pharmaceutical spending in China, and with incentive policies, the market size of the generic drug continues to rise.
Chen Yina, Liu Pengcheng, Nie Haomiao, Cao Yang   +3 more
doaj   +1 more source

Pricing and reimbursement of orphan drugs: the need for more transparency

Orphanet Journal of Rare Diseases, 2011
Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, legislators, health care professionals, industry leaders, academics and patients.
Simoens Steven
doaj   +1 more source

Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care

Frontiers in Digital Health, 2021
The SARS-Cov-2 pandemic placed a dramatic burden on managed healthcare and perhaps nowhere as evident as in neurological and psychiatric disease care.
Amit Khanna, Graham B. Jones, Graham B. Jones   +2 more
doaj   +1 more source

The evaluation of a Taiwanese training program in smoking cessation and the trainees' adherence to a practice guideline

BMC Public Health, 2010
Background The Taiwanese government began reimbursement for smoking cessation in 2002. Certification from a training program was required for physicians who wanted reimbursement. The program certified 6,009 physicians till 2007.
Leung Kai-Kuen, Chang Chih-Jen, Hung Ling-Yu, Guo Fei-Ran, Chen Ching-Yu   +4 more
doaj   +1 more source

Incentives and Pharmaceutical Reimbursement Reforms in Spain [PDF]

SSRN Electronic Journal, 2003
The aim of this paper is to assess whether cost containment has been affected by recent pharmaceutical reimbursement reforms that have been introduced in the Spanish health care system over the period 1996-2002, under the conservative Popular Party Government.
openaire   +4 more sources